Lithium is a commonly used mood-stabilizing agent primarily used to manage conditions involving episodic or fluctuating manifestations, most notably Bipolar Disorder (Manic-Depressive Illness). Its main use is commonly to help with the management of manic episodes and to assist with the prevention of their recurrence.

It is applied across domains where additional symptomatic support is needed, relevant for acute episodes, long-term maintenance of mood stability, and as a supportive addition for depression that is resistant to treatment. The primary therapeutic domain is in providing support that helps ease the overall symptom burden of cyclical mood instability. It helps address symptom clusters that may become intense or disruptive, such as periods of high excitement and rapid thought patterns, which supports patients during difficult episodes by easing distress. It is commonly used to address symptoms associated with significant distress, including recurrent self-harming behaviors and thoughts.

---

Quick Fact: Relief for Cyclical Mood Instability

Symptom Category	Therapeutic Benefit
Acute Mania	Helps manage intense symptoms (e.g., hyperactivity, racing thoughts).
Mood Cycling	Supports reducing the frequency and severity of future episodes (prophylaxis).
High Risk	Commonly used to help with the management of recurrent suicidal thoughts.

Regulatory References

1. MedlinePlus Drug Information overview

Official Eligibility Rules for Lithium Use

Regulatory documents define specific populations who are permitted, restricted, or prohibited from using Lithium, based primarily on organ function and age.

Eligibility Status	Population or Condition (Based on Official Labeling)
Absolute Contraindication (Must Not Use)	Patients with severe renal impairment or significant cardiovascular disease [FDA Source 1.1]. Patients with Brugada Syndrome or suspected Brugada Syndrome [FDA Source 1.1]. Patients who are sodium-depleted (e.g., severe dehydration or on a low-sodium diet) [FDA Source 1.1]. Patients with Addison’s disease [Source 1.5].
Restricted/Conditional Use	Patients with mild to moderate renal impairment (requires caution and frequent monitoring) [FDA Source 1.3]. Patients with pre-existing thyroid disorders [FDA Source 1.1]. Older adults (geriatric patients) are eligible but often require a reduced dosage [FDA Source 4.1].
Not Recommended	Nursing mothers [FDA Source 1.4]. Pregnant women (use restricted due to potential for fetal harm, particularly cardiac anomalies) [FDA Source 1.4]. Children under 12 years of age (safety and effectiveness not established) [FDA Source 4.3].

Eligibility is also affected by conditions that cause acute sodium or water loss, such as fever or protracted sweating, which may necessitate a temporary cessation or reduction of the medicine to avoid toxicity. Lithium is generally used in adults and adolescents aged 12 years and older (U.S. labeling).

Interactions with other medicines and products

Category	Official Regulatory Information
Medicinal product categories with documented interactions	Diuretics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Angiotensin-Converting Enzyme (ACE) Inhibitors, Serotonergic Drugs, Neuroleptic Drugs, Neuromuscular Blocking Agents.
Mechanistic basis of interactions (only if stated in label)	Reduced renal clearance (leading to increased serum levels); Additive Pharmacodynamic Effect (e.g., risk of Serotonin Syndrome); Pharmacodynamic/Neurotoxicity (e.g., risk of Encephalopathic Syndrome).
Interaction-related restrictions	Avoidance is formally advised for co-administration with drugs that Prolong the QT Interval. Co-administration with certain Antipsychotics is stated to be avoided by some regulatory authorities.

---

Resulting Interaction Structure

Official regulatory documents define the Lithium interaction structure primarily through two domains: pharmacokinetic interactions and pharmacodynamic interactions.

Pharmacokinetic interactions increase drug exposure by reducing the renal clearance of the Lithium ion. This occurs with medications such as Diuretics (e.g., Thiazides), NSAIDs (e.g., Indomethacin, Piroxicam), ACE Inhibitors, and Angiotensin II Receptor Antagonists. Antibiotics like Metronidazole and Tetracyclines are also documented to increase serum concentrations.

Pharmacodynamic interactions enhance central nervous system effects. This includes the increased risk of Serotonin Syndrome when combined with Serotonergic Drugs (including the herbal product St. John's Wort), and the risk of Encephalopathic Syndrome with certain Neuroleptic Drugs. The official profile emphasizes that Sodium Depletion or Volume Depletion significantly exacerbates the risk of exposure-related toxicity.

How Lithium Works

The Lithium ion ( Li^+) operates through a multi-target action on fundamental cellular processes, primarily focusing on regulating nerve cell function and enhancing long-term protective mechanisms.

---

Intracellular Signal Dampening and Stabilization

The drug's action involves inhibiting key enzymes, specifically Inositol Monophosphatase ( IMPase), involved in recycling the signaling molecule inositol. This restriction of the Phosphatidylinositol ( PI) pathway acts to dampen the over-amplification of nerve cell signals, promoting stabilization of physiological signaling by reducing excessive communication within overactive neural circuits.

---

Neuroprotection and Synaptic Plasticity Enhancement

A secondary mechanism involves Lithium acting as an inhibitor of the regulatory enzyme Glycogen Synthase Kinase-3 ( GSK-3beta). This inhibition initiates a cellular cascade that promotes the production of protective proteins ( Bcl-2) and growth factors ( BDNF), fostering neuronal protective mechanisms and the formation of new synaptic connections.

---

️ Modulation of Ionic and Neurotransmitter Balance

Lithium exerts a broad modulating influence on the nerve cell environment, competing with Sodium ions to regulate membrane excitability while simultaneously adjusting the balance of chemical messengers. This activity helps shift the CNS away from excessive excitatory signaling ( Glutamate) toward more regulated, inhibitory activity ( GABA).

Lithium is administered strictly by the oral route as a capsule, tablet (immediate- or extended-release), or solution. The dosing regimen is highly individualized and is determined by achieving specific serum lithium concentrations.

Treatment Phase	Typical Adult Daily Dose Range	Target Serum Lithium Level
Acute Mania	Up to 1800 mg/day in divided doses	1.0 to 1.5 mEq/L
Maintenance	900 mg to 1200 mg/day	0.6 to 1.2 mEq/L

The medication is typically taken in divided doses during the initial acute phase, though maintenance therapy may allow for a once daily schedule, particularly with extended-release forms. Administration may be done with food to minimize potential gastrointestinal discomfort.

Administration Requirements

The dosage is adjusted based on serum concentration assay. Blood samples must be drawn precisely 8 to 12 hours after the last dose (trough level) to ensure an accurate measurement that reflects drug concentration stability. During the initial stabilization period, the instruction is to maintain both adequate fluid intake and a normal, consistent dietary salt intake.

Specific handling rules apply to formulations: extended-release tablets must be swallowed whole and should not be crushed, split, or chewed. Older adults and patients with mild to moderate renal impairment often require lower starting dosages and more frequent monitoring to maintain target serum levels.

Research evidence / Overview of Studies for Lithium

---

Evidence for Preventing Recurrence of Mood Episodes

According to summaries provided by major regulatory bodies, research exploring lithium's use in individuals with Bipolar Disorder primarily involves numerous long-term Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews. These studies monitored outcomes related to episode recurrence, specifically tracking the time elapsed before the next manic, depressive, or mixed episode, and observing the overall rate of re-hospitalization in adult populations. Findings describe patterns where study participants, compared to control groups, were observed to have differences in the time until a new mood episode.

However, comparative evidence against all newer active comparator medicines is lacking over equivalent long follow-up durations. The completeness of the long-term follow-up data is sometimes influenced by the fact that participant withdrawal or discontinuation was common in the studies, leading to high discontinuation rates being reported.

---

Research Evidence on Suicidality and Self-Harm

The research base exploring lithium's association with reducing the risk of suicide and self-harming behavior is primarily derived from combining data from multiple sources. This includes Systematic Reviews and Meta-analyses that pool findings from long-term RCTs that included suicidality as a measured outcome, alongside evidence from large Long-term Observational Studies. These studies monitored outcomes related to both completed suicide and non-fatal events like attempted suicide or self-directed violence.

Findings describe group patterns observed in these studies, consistently reporting that researchers tracked differences in the measured rates of suicide attempts between the studied populations and control conditions. Observational studies consistently described measurements of the incidence rates of suicide-related mortality across large patient groups tracked over many years.

---

Known Research Gaps and Remaining Uncertainties

Limited data are available for certain subgroups, such as those with frequently recurring or rapid-cycling forms of Bipolar Disorder. Data for certain age groups remain insufficient, especially concerning the long-term outcomes and durability of response in children, adolescents, and older adults compared to the general adult population. Evidence quality varies across studies, particularly in older trials, due to differing protocols and variability in patient populations. Studies help show what has been observed so far, but research does not determine whether an individual will respond similarly.

Key Studies & References Bipolar disorder: assessment and management (NICE Guideline CG185)

Common questions about Lithium (FAQ)

---

Q: How quickly does Lithium start to work?

Information from clinical experience suggests that some initial effects of Lithium may be observed within the first 1 to 3 weeks. However, the full intended stabilizing benefit is generally seen after several weeks to months of consistent use.

---

Q: Why does my healthcare provider need to do blood tests while I take Lithium?

Lithium has a narrow therapeutic index, meaning the effective dose is close to the dose that can cause side effects or toxicity. Regular blood tests are necessary to measure the lithium level (concentration) in the blood. This helps a healthcare professional determine if the concentration is within the established therapeutic range for that individual.

---

Q: Can I take over-the-counter pain relievers (like ibuprofen) while on Lithium?

Certain common medications, particularly some nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen, may interact with Lithium. These interactions could potentially lead to an increase in lithium levels, raising the risk of side effects. It is important to consult a healthcare provider or pharmacist before taking any new over-the-counter medications, including pain relievers.

---

Q: What happens if I miss a dose of Lithium?

If a dose is missed, the prescribing information often recommends taking the missed dose as soon as it is remembered, unless it is close to the time for the next scheduled dose. If it is almost time for the next dose, it is generally recommended to skip the missed dose and resume the normal schedule. Double dosing is generally advised against. This specific guidance should always be confirmed by a healthcare professional.

---

Q: What precautions should I take regarding fluid intake while on Lithium?

Maintaining a consistent fluid and salt intake is often recommended while taking Lithium. Significant changes in hydration status—such as becoming dehydrated due to illness, heavy exercise, or high heat—can potentially affect lithium levels in the body. Consult a healthcare provider for personalized advice on hydration and diet while on this medication.

How to Store and Dispose of Lithium

Storage Requirements

Lithium-containing medications must be stored at Controlled Room Temperature, defined as 20^circ to 25 C (68^circ to 77 F), with permitted excursions up to 30 C. The product must be protected from moisture and kept in its original package, with the container tightly closed to maintain stability. Do not use the product if the outer packaging, such as a blister, is torn or broken. As with all medications, ensure Lithium is stored securely out of the sight and reach of children.

---

Disposal Procedures

Unused or expired product should be disposed of using a drug take-back program when available. If a take-back program is not accessible, the FDA advises mixing the medicine with an unappealing substance, placing the mixture in a sealed bag or container, and discarding it in the household trash. Always scratch out personal information from prescription labels before disposal.